Literature DB >> 9525668

Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.

C M O'Neal1, J D Clements, M K Estes, M E Conner.   

Abstract

We have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin (CT) induced protection from rotavirus challenge, as measured by virus shedding. Since it is unclear if CT will be approved for human use, we evaluated the adjuvanticity of Escherichia coli heat-labile toxin (LT) and LT-R192G. Mice were inoculated intranasally with 10 microg of 2/6-VLPs combined with CT, LT, or LT-R192G. All three adjuvants induced equivalent geometric mean titers of rotavirus-specific serum antibody and intestinal immunoglobulin G (IgG). Mice inoculated with 2/6-VLPs with LT produced significantly higher titers of intestinal IgA than mice given CT as the adjuvant. All mice inoculated with 2/6-VLPs mixed with LT and LT-R192G were totally protected (100%) from rotavirus challenge, while mice inoculated with 2/6-VLPs mixed with CT showed a mean 91% protection from challenge. The availability of a safe, effective mucosal adjuvant such as LT-R192G will increase the practicality of administering recombinant vaccines mucosally.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525668      PMCID: PMC109829          DOI: 10.1128/JVI.72.4.3390-3393.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  12 in total

1.  Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells.

Authors:  S E Crawford; M Labbé; J Cohen; M H Burroughs; Y J Zhou; M K Estes
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

Review 2.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

3.  Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop.

Authors:  V Giannelli; M R Fontana; M M Giuliani; D Guangcai; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

4.  Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus.

Authors:  N Feng; J W Burns; L Bracy; H B Greenberg
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures.

Authors:  J D Clements; R A Finkelstein
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

6.  Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice.

Authors:  M A Franco; H B Greenberg
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

7.  Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.

Authors:  J D Clements; N M Hartzog; F L Lyon
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

8.  Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity.

Authors:  S Yamamoto; Y Takeda; M Yamamoto; H Kurazono; K Imaoka; M Yamamoto; K Fujihashi; M Noda; H Kiyono; J R McGhee
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

9.  Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin.

Authors:  Y Lobet; C W Cluff; W Cieplak
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

10.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.

Authors:  B L Dickinson; J D Clements
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more
  32 in total

1.  Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

Authors:  Fu-Shi Quan; Chunzi Huang; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

2.  Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.

Authors:  Nathalie Parez; Cynthia Fourgeux; Ali Mohamed; Catherine Dubuquoy; Mathieu Pillot; Axelle Dehee; Annie Charpilienne; Didier Poncet; Isabelle Schwartz-Cornil; Antoine Garbarg-Chenon
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity.

Authors:  Sarah E Blutt; Kelly L Warfield; Mary K Estes; Margaret E Conner
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

4.  Immune mediators of rotavirus antigenemia clearance in mice.

Authors:  Glendie Marcelin; Amber D Miller; Sarah E Blutt; Margaret E Conner
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

5.  Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Authors:  Audrey Glynn; Chad J Roy; Bradford S Powell; Jeffrey J Adamovicz; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice.

Authors:  Davide Agnello; Christine A Hervé; Amandine Lavaux; Magali Darniot; Patrice Guillon; Annie Charpilienne; Pierre Pothier
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.

Authors:  Fu-Shi Quan; Gangadhara Sailaja; Ioanna Skountzou; Chunzi Huang; Andrei Vzorov; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2007-02-15       Impact factor: 3.641

Review 8.  Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.

Authors:  Cynthia A Lemere; Edward T Spooner; Jodi F Leverone; Chica Mori; Melitza Iglesias; Jeanne K Bloom; Timothy J Seabrook
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

Review 9.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

10.  Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection.

Authors:  Marli S P Azevedo; Lijuan Yuan; Cristiana Iosef; Kyeong-Ok Chang; Yunjeong Kim; Trang Van Nguyen; Linda J Saif
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.